Serum biomarkers of hepatocellular carcinoma in patients with liver cirrhosis: a narrative review

Mohamed, Salem Youssef; Esmaiel, Ahmed Elsayed; Shabana, Marwa Abo; Ibrahim, Nevin Fouad

doi:10.21608/ajgh.2021.210293

	Serum biomarkers of hepatocellular carcinoma in patients with liver cirrhosis: a narrative review
African Journal of Gastroenterology and Hepatology
Article 5, Volume 4, Issue 1, July 2021, Page 33-43
Document Type: Mini-reviews Articles
DOI: 10.21608/ajgh.2021.210293
View on SCiNiTO
Authors
Salem Youssef Mohamed ¹; Ahmed Elsayed Esmaiel ²; Marwa Abo Shabana³; Nevin Fouad Ibrahim⁴
¹Internal Medicine Department, gastroenterology and hepatology unit, faculty of medicine, zagazig university, Egypt
²Liver center, ministry of health, Kafr Elsheikh, Egypt
³Clinical Pathology Department, Faculty of Medicine, Zagazig University, Egypt
⁴Internal Medicine Department, Faculty of Medicine, Zagazig University, Egypt
Abstract
Background: Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide and the most frequent type of primary liver cancer. HCC is diagnosed in the laboratory using either fine-needle cytology, which is invasive and has intra- or inter-observer variability or measuring circulating biomarkers. In combination with ultrasonography and computed tomography, several prognostic and diagnostic indicators are helpful in the clinical practice of screening and diagnosing HCC. Aim of work: To give an overview of serum biomarkers of HCC.
Keywords
Hepatocellular Carcinoma; Cirrhosis; Serological Markers; Alpha-fetoprotein
Supplementary Files Serum biomarkers of hepatocellular carcinoma in patients with liver cirrhosis.docx

References
1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301– 14. 2. El-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single-center study over a decade. World J Gastroenterol. 2005;11(33):5193 3. Stivala AC, Dronamraju DA, and Dieterich DT. Hepatitis C: Diagnosis, Management, and Treatment. Mount Sinai Expert Guides: Hepatology. Hepatol. 2014:58-77. 4. Dhanasekaran RO, Bandoh SA and Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;54-5. 5. Heidenreich BA, Nagore EM, Rachakonda PS, G, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014;5(1):1-7. 6. Schueller FO, Roy SA, Vucur MU, Trautwein CO, Luedde TA and Roderburg CE. The role of miRNAs in the pathophysiology of liver diseases and toxicity. Int J Mol Sci. 2018;19(1):261. 7. Cho SA, Kim HS, Zeiger MA, Umbricht CB and Cope LM. Measuring DNA copy number variation using high-density methylation microarrays. J Comput Biol. 2019;26(4):295-304. 8. Dimitroulis DA, Damaskos CE, Valsami SO, et al.From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for developed and developing countries. World J Gastroenterol. 2017;23(29):5282. 9. Chia TS, Wong KF and Luk JM. Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection. Hepatoma Res. 2019;29-5. 10. Balachandrakumar VK, Jabbar NF, White DA, and Stern NU. Diagnosis and Staging of Hepatocellular Carcinoma (HCC). Liver Canc. 2019;67-82. 11. Ronot MA and Vilgrain VO. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. Best Pract Res Clin Gastroenterol. 2014;28(5):795-812. 12. Ayuso CO, Rimola JU, Vilana RI, et al.Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018; 101:72-81. 13. Rich NA and Singal AG. Hepatocellular carcinoma tumor markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28(5):843-53. 14. Kim YS, Lim HK, Rhim HU, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58(1):89-97. 15. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosing hepatocellular carcinoma in chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34:570-575. 16. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: an analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000; 31:302-308. 17. Zhang YS, Chu JH, Cui SX, Song ZY, and Qu XJ. Des-γ-carboxy prothrombin (DCP) is a potential autologous growth factor for the development of hepatocellular carcinoma. Cell PhysiolBiochem. 2014;34(3):903-15. 18. Feng MA and Ho MU. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS lett. 2014;588(2):377-82. 19. Peng WA, Zhao JO, Dong XA, Banazadeh AR, Huang YA, Hussien AT, et al. Clinical application of quantitative glycomics. Expert Rev Proteom. 2018;15(12):1007-31. 20. Catanzaro JM, Guerriero JL, Liu JO, Ullman EL, Sheshadri NA, Chen JJ, et al.Elevated expression of squamous cell carcinoma antigen (SCCA) is associated with human breast carcinoma. PloS One. 2011;6(4): e19096. 21. Singh AR and Settleman JE. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-51. 22. Zhang LI, Jin YU, Huang MA and Penning TM. The role of human aldo-keto reductases in the metabolic activation and detoxication of polycyclic aromatic hydrocarbons: interconversion of PAH catechols and PAH o-quinones. Front Pharmacol. 2012;3-193. 23. Radwan MI, Pasha HF, Mohamed RH, Hussien HI and El-Khshab MN. Influence of transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60(1):271-6. 24. Ozkan HI, Erdal HA, Tutkak HU, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2010;83(1-2):83. 25. Johnson KE and Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care. 2014;3(10):647-61. 26. Edwards SP, Lalor PF, Tuncer CA and Adams DH. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an α v β 3-independent manner. Br J Cancer. 2006;95(11):1545-54. 27. Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol. 2008;14(39):6072–6077. 28. Duan J, Wu Y, Liu J, et al. Genetic Biomarkers for HepatocellularCarcinoma in The Era of Precision Medicine.Journal of Hepatocellular Carcinoma. 2019:6. 29. Berhane S, Toyoda H, Tada T, et al.Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.Clin Gastroenterol Hepatol 2016 Jun;14(6):875-886. 30. Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109(6):1657-65. 31. Kulik LA and El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterol. 2019;156(2):477-91. 32. Matsukuma KE and Yeh MM. Update on the pathology of liver neoplasms. Ann Diagn Pathol. 2019; 38:126-37. 33. Esmaiel A. Is it time now to stop searching for other tumor markers for HCC apart from alpha-fetoprotein? African journal of gastroenterology and hepatology [Internet]. The Scientific Society of Kafrel-sheik Doctors; 2021 October 12;4(1):26-28. Available from: http://dx.doi.org/10.52378/fkha1952.
Statistics Article View: 442 PDF Download: 22